A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether salvage pulmonary resection is possible and worthwhile for patients with recurrence of non-small-cell lung cancer (NSCLC) after prior definitive non-operative therapy. A total of nine reports were identified using the reported search, of which four represented the best available evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. All studies were retrospective. In total, 48 pulmonary salvage resections were performed in 47 patients after prior definitive radiation, chemoradiation or stereotactic body radiation therapy, of which 28 were lobectomies (including 1 sleeve lobectomy), 12 pneumonectomies, 4 bilobectomies and 4 sublobar resections (2 segmentectomies and 2 wedge resections). Postoperative complications ranged from 0 to 58% (mean from four studies 42.5%). Only one study reported any mortality (4%), the other three had zero mortality. Median postoperative survival was reported in two studies and ranged from 9 to 30 months. Experience with salvage lung resection for locally recurrent NSCLC, after prior definitive non-surgical treatment, remains limited. Therefore, this analysis was based on only 48 resections in 47 patients from four retrospective studies. Nevertheless, the published data suggest that salvage lung surgery for recurrent, previously non-operatively managed non-small-cell lung cancer is a worthwhile treatment option with good survival, acceptable morbidity and low mortality.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A 56-year old female patient completed definitive chemoradiation (62 Gy) for a centrally located left upper lobe stage IIb adenocarcinoma 13 months ago. She has been able to carry out most of her daily activities ever since. A 6-month follow-up (18) F-fluorodeoxyglucose positron emission tomography (FDG-PET) demonstrated neither increased metabolic activity in the lungs nor suspicious metastases. Now, her 18-month follow-up FDG-PET shows a well-circumscribed 1.9-cm hypermetabolic area with the standard uptake value of 8.4, centrally located in the left upper lobe, presumed to be a local tumour recurrence. Her treatment options include surgical resection, chemotherapy, re-irradiation, radiosurgery and/or radiofrequency ablation. Given her good performance status, you are keen to proceed with the left upper lobectomy but the patient is concerned that she will not survive long after the operation. You resolve to review the current literature. 
SEARCH STRATEGY
SEARCH OUTCOME
Nine papers were found using the reported search. From these, four papers were identified that provided the best evidence to answer the above question. These are detailed in Table 1 . 
RESULTS
Bauman et al. [2] retrospectively analysed the outcomes of salvage surgery in 24 patients with local recurrence of NSCLC in pretreatment stage IIb/IIIa, initially managed with definitive radiation (n = 2) or chemoradiation (n = 22) with a total radiation dose of >59 Gy. The authors reported a perioperative mortality of 4% (n = 1) and a high rate (58%) of perioperative complications (n = 24). The calculated median disease-free interval was 5 months. The median postoperative survival was 30 months and the estimated 3-year survival was 47%. A higher survival was observed among patients undergoing early salvage resection for abnormal FDG-PET than for obvious relapse by computed tomography (CT) (43 vs 12 months, P = 0.019). Kuzmik et al. [3] studied 14 patients, who underwent salvage lung resections after prior curative intent definitive chemoradiation for local (54%) and distant (46%) NSCLC relapse. The median disease-free interval after the last dose of chemoradiation was 33 months. The median postoperative survival was 9 months and the estimated 2-year survival was 49%. No variables were found to be associated with improved postoperative survival.
Chen et al. [4] reported on 5 patients, who underwent salvage lung resection for local NSCLC recurrence after stereotactic body radiotherapy (SBRT) with the biological effective radiation dose of 105.6 Gy at the isocentre of the lesion. The mean interval between the SBRT and salvage surgery was 32.8 months (range 10-104 months). The median disease-free interval was not calculated. The postoperative course was uneventful in all patients. After a median postoperative follow-up of 27 months, all patients were alive.
Allibhai et al. [5] described 4 patients who underwent salvage lobectomy [3 via video-assisted thoracoscopic surgery (VATS), 1 open] for local NSCLC recurrence or tumour progression after previous SBRT. The pretreatment NSCLC stage was T1-T2N0M0, but initially all 4 patients were inoperable due to their comorbidities (recent coronary event, cerebrovascular event, severe pulmonary disease, diabetes). The radiation dose at the initial treatment ranged between 48 and 60 Gy. The disease-free interval ranged from 10 to 25 months. The authors report no significant intraoperative or postoperative complications. All patients remain alive without tumour relapse after a median follow-up of 30 months. The authors concluded that inoperability is not always fixed and irreversible and surgical salvage should also be considered in patients previously felt to be inoperable.
Three other papers on salvage surgery for recurrent NSCLC after prior definitive non-operative management were found [6] [7] [8] . However, due to insufficient number of cases, unclearly specified indications for salvage surgery or lacking outcome data, they were not included in our review.
CLINICAL BOTTOM LINE
Experience with salvage lung resection for locally recurrent NSCLC, after prior definitive non-surgical treatment, remains limited. Nevertheless, the published data suggest that salvage lung surgery for recurrent, previously non-operatively managed non-small-cell lung cancer is a worthwhile treatment option with good survival, acceptable morbidity and low mortality. Early salvage resections for abnormal FDG-PET result in higher patient survival than those for obvious relapse by CT.
